Stay updated on Pyrotinib+CDK4/6 Inhibitor in Trastuzumab-Prior HER2+ Breast Ca Clinical Trial

Sign up to get notified when there's something new on the Pyrotinib+CDK4/6 Inhibitor in Trastuzumab-Prior HER2+ Breast Ca Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pyrotinib+CDK4/6 Inhibitor in Trastuzumab-Prior HER2+ Breast Ca Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    8 days ago
    No Change Detected
  3. Check
    15 days ago
    Change Detected
    Summary
    Added a Locations section listing Brazilian sites in Paraná, Rio Grande do Sul, and São Paulo, with the Revision: v3.3.3 tag.
    Difference
    0.4%
    Check dated 2025-12-23T10:18:11.000Z thumbnail image
  4. Check
    22 days ago
    No Change Detected
  5. Check
    44 days ago
    Change Detected
    Summary
    Revision label in the page footer updated from v3.2.0 to v3.3.2. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2025-11-24T17:07:59.000Z thumbnail image
  6. Check
    51 days ago
    Change Detected
    Summary
    Removed the generic government funding/operating status notice from the page. The study details, enrollment criteria, and primary outcomes appear unchanged.
    Difference
    0.4%
    Check dated 2025-11-17T15:06:04.000Z thumbnail image
  7. Check
    65 days ago
    Change Detected
    Summary
    The Study Details page appears unchanged between the two screenshots, with no significant content additions or removals detected.
    Difference
    0.5%
    Check dated 2025-11-03T01:33:56.000Z thumbnail image
  8. Check
    94 days ago
    Change Detected
    Summary
    Added a government-operations notice and updated to version v3.2.0, replacing the previous v3.1.0.
    Difference
    4%
    Check dated 2025-10-05T10:36:39.000Z thumbnail image
  9. Check
    101 days ago
    Change Detected
    Summary
    Updated to Revision: v3.1.0 and removed several drug-safety topics (Drug Safety, Counterfeit Drugs, Pharmaceutical Preparations, Substandard Drugs) while keeping the revision label as the primary addition.
    Difference
    0.4%
    Check dated 2025-09-28T03:25:19.000Z thumbnail image

Stay in the know with updates to Pyrotinib+CDK4/6 Inhibitor in Trastuzumab-Prior HER2+ Breast Ca Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pyrotinib+CDK4/6 Inhibitor in Trastuzumab-Prior HER2+ Breast Ca Clinical Trial page.